SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: A novel class of drugs termed “JAK inhibitors” (JAKi) has recently been developed primarily for chronic inflammatory diseases, but there is substantial evidence of JAK/STAT pathway overactivation also in CTCL.